Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture
- PMID: 8384186
Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture
Abstract
In a randomized, placebo-controlled, double blind study, 180 obese patients were treated by diet (4.2 MJ/day) and either an ephedrine/caffeine combination (20mg/200mg), ephedrine (20mg), caffeine (200mg) or placebo 3 times a day for 24 weeks. 141 patients completed this part of the study. All medication was stopped between week 24-26 in order to catch any withdrawal symptoms. From week 26 to 50, 99 patients completed treatment with the ephedrine/caffeine compound in an open trial design, resulting in a statistically significant (p = 0.02) weight loss of 1.1kg. In another randomized, double-blind, placebo-controlled 8 week study on obese subjects we found the mentioned compound showed lean body mass conserving properties. We conclude that the ephedrine/caffeine combination is effective in improving and maintaining weight loss, further it has lean body mass saving properties. The side effects are minor and transient and no withdrawal symptoms have been found.
Similar articles
-
The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial.Int J Obes Relat Metab Disord. 1992 Apr;16(4):269-77. Int J Obes Relat Metab Disord. 1992. PMID: 1318281 Clinical Trial.
-
The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans.Int J Obes Relat Metab Disord. 1993 Dec;17 Suppl 3:S73-7; discussion S82. Int J Obes Relat Metab Disord. 1993. PMID: 8124407 Clinical Trial.
-
Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice.Int J Obes Relat Metab Disord. 1994 Feb;18(2):99-103. Int J Obes Relat Metab Disord. 1994. PMID: 8148931 Clinical Trial.
-
Herbal simulation of ephedrine and caffeine in treatment of obesity.Int J Obes Relat Metab Disord. 2002 May;26(5):590-2. doi: 10.1038/sj.ijo.0802036. Int J Obes Relat Metab Disord. 2002. PMID: 12032740 Review. No abstract available.
-
Clinical aspects of ephedrine in the treatment of obesity.Int J Obes Relat Metab Disord. 1993 Feb;17 Suppl 1:S65-8. Int J Obes Relat Metab Disord. 1993. PMID: 8384185 Review. No abstract available.
Cited by
-
Antiobesity drugs: current and future issues.Curr Diab Rep. 2002 Oct;2(5):409-15. doi: 10.1007/s11892-002-0105-3. Curr Diab Rep. 2002. PMID: 12643166 Review.
-
Twelve weeks supplementation with an extended-release caffeine and ATP-enhancing supplement may improve body composition without affecting hematology in resistance-trained men.J Int Soc Sports Nutr. 2016 Jun 10;13:25. doi: 10.1186/s12970-016-0136-9. eCollection 2016. J Int Soc Sports Nutr. 2016. PMID: 27293386 Free PMC article. Clinical Trial.
-
Thermogenic drugs as a strategy for treatment of obesity.Endocrine. 2000 Oct;13(2):207-12. doi: 10.1385/ENDO:13:2:207. Endocrine. 2000. PMID: 11186222 Review.
-
Adulteration of Weight Loss Supplements by the Illegal Addition of Synthetic Pharmaceuticals.Molecules. 2021 Nov 16;26(22):6903. doi: 10.3390/molecules26226903. Molecules. 2021. PMID: 34833995 Free PMC article.
-
Pharmacotherapy for childhood obesity: present and future prospects.Int J Obes (Lond). 2013 Jan;37(1):1-15. doi: 10.1038/ijo.2012.144. Epub 2012 Aug 28. Int J Obes (Lond). 2013. PMID: 22929210 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical